Evidence map›Paper›PMID 37858679›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2023

Visual Assessment of 2-Dimensional Levels Within 3-Dimensional Pathology Data Sets of Prostate Needle Biopsies Reveals Substantial Spatial Heterogeneity.

Can Koyuncu, Andrew Janowczyk, Xavier Farre, Tilak Pathak, Tuomas Mirtti, Pedro L Fernandez, Laura Pons, Nicholas P Reder, Robert Serafin, Sarah S L Chow and 5 more

Abstract read
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Can KoyuncuDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia.
Andrew JanowczykDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia; Department of Oncology, Division of Precision Oncology, University Hospital of Geneva, Geneva, Switzerland; Department of Clinical Pathology, Division of Clinical Pathology, University Hospital of Geneva, Geneva, Switzerland.
Xavier FarrePublic Health Agency of Catalonia, Lleida, Catalonia, Spain.
Tilak PathakDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia.
Tuomas MirttiDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia; Department of Pathology, University of Helsinki and Helsinki University, Hospital, Helsinki, Finland; Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; iCAN-Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Pedro L FernandezDepartment of Pathology, Hospital Germans Trias i Pujol, IGTP, Universidad Autonoma de Barcelona, Barcelona, Spain.
Laura PonsDepartment of Pathology, Hospital Germans Trias i Pujol, IGTP, Barcelona, Spain.
Nicholas P RederDepartment of Mechanical Engineering, University of Washington, Seattle, Washington; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, Washington.
Robert SerafinDepartment of Mechanical Engineering, University of Washington, Seattle, Washington.
Sarah S L ChowDepartment of Mechanical Engineering, University of Washington, Seattle, Washington.
Vidya S ViswanathanDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia.
Adam K GlaserDepartment of Mechanical Engineering, University of Washington, Seattle, Washington.
Lawrence D TrueDepartment of Laboratory Medicine & Pathology, University of Washington, Seattle, Washington; Department of Urology, University of Washington, Seattle, Washington.
Jonathan T C LiuDepartment of Mechanical Engineering, University of Washington, Seattle, Washington; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, Washington; Department of Bioengineering, University of Washington, Seattle, Washington.
Anant MadabhushiDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia; Atlanta VA Medical Center, Atlanta, Georgia. Electronic address: anantm@emory.edu.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
NCCIH Supplement to NCATS/CTSA Program for KL2 Scholars - M. SoddersKL2TR002317 · NCATS · UNIVERSITY OF WASHINGTON · PI Christy Michelle McKinney · 2017 to 2026
$14.5M
KPMP Kidney Mapping and Atlas Project (KMAP)U01DK133090 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$10.4M
NRSA Training CoreTL1TR002318 · NCATS · UNIVERSITY OF WASHINGTON · PI Megan Moore · 2017 to 2026
$8.4M
Pathology CoreU54CA254566 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 2020 to 2024
$5.0M
Computer-Assisted Histologic Evaluation of Cardiac Allograft RejectionR01HL151277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MADABHUSHI, ANANT, MARGULIES, KENNETH BER · 2020 to 2023
$3.2M
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Prostate cancer risk stratification via computational 3D pathologyR01CA268207 · NCI · UNIVERSITY OF WASHINGTON · PI Jonathan T.C. Liu, Anant Madabhushi · 2022 to 2026
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
Prognostic and Predictive Digital Tissue Image Assay for Prostate CancerR01CA268287 · NCI · EMORY UNIVERSITY · PI GUPTA, SHILPA, LAL, PRITI · 2022 to 2025
$3.0M
BLRD VA I01 BX004121BLRD VA IK6 BX006185CSRD VA I01 CX002622NCATS NIH HHS KL2 TR002317NCATS NIH HHS TL1 TR002318NCI NIH HHS K99 CA240681NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220581NCI NIH HHS R01 CA249992NCI NIH HHS R01 CA257612NCI NIH HHS R01 CA268207NCI NIH HHS R01 CA268287NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U01 CA269181NCI NIH HHS U24 CA199374NCI NIH HHS U54 CA254566NHLBI NIH HHS R01 HL151277NHLBI NIH HHS R01 HL158071NIBIB NIH HHS R01 EB031002NIBIB NIH HHS R43 EB028736NIDDK NIH HHS U01 DK133090NLM NIH HHS R01 LM013864
6 · The paper itself

Abstract

Prostate cancer prognostication largely relies on visual assessment of a few thinly sectioned biopsy specimens under a microscope to assign a Gleason grade group (GG). Unfortunately, the assigned GG is not always associated with a patient's outcome in part because of the limited sampling of spatially heterogeneous tumors achieved by 2-dimensional histopathology. In this study, open-top light-sheet microscopy was used to obtain 3-dimensional pathology data sets that were assessed by 4 human readers. Intrabiopsy variability was assessed by asking readers to perform Gleason grading of 5 different levels per biopsy for a total of 20 core needle biopsies (ie, 100 total images). Intrabiopsy variability (Cohen κ) was calculated as the worst pairwise agreement in GG between individual levels within each biopsy and found to be 0.34, 0.34, 0.38, and 0.43 for the 4 pathologists. These preliminary results reveal that even within a 1-mm-diameter needle core, GG based on 2-dimensional images can vary dramatically depending on the location within a biopsy being analyzed. We believe that morphologic assessment of whole biopsies in 3 dimension has the potential to enable more reliable and consistent tumor grading.

Indexed as

ProstateProstatic NeoplasmsBiopsyBiopsy, Large-Core NeedleHumansMaleNeoplasm Grading3D pathologyGleason gradingGleason grading variabilityintrabiopsy variabilityprostate cancer

Identifiers

PMID37858679
PMCPMC10926776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.